Particle Size Project (EPSOM)

April 12, 2022 updated by: Duke University

Effects of Increased Chewing Efficiency on the Gut Microbiome

This study is designed to test the effects of chewing efficiency on human gut microbiome composition and function.

Study Overview

Detailed Description

Our working hypothesis is that increased chewing will lead to an increase in short-chain fatty acid production We further expect this effect to lead to a detectable decrease in fecal particle size and distinct changes in gut microbial community composition. Here, we will explore this hypothesis using a fixed-order within-subjects study design in a group of healthy participants. Each participant will have one week of normal dietary habits and one week of increased chewing time. We will collect stool samples three times per week in order to measure microbial abundance and metabolism.

Study Type

Interventional

Enrollment (Actual)

41

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

    • North Carolina
      • Durham, North Carolina, United States, 27708
        • Duke University

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years and older (Adult, Older Adult)

Accepts Healthy Volunteers

Yes

Genders Eligible for Study

All

Description

Inclusion Criteria:

  • Above age 18?
  • Able to provide stool samples at no risk to yourself?
  • Do you have card access to the CIEMAS building (work in CIEMAS, in Pratt School, or undergraduate at Duke), and are you able to visit this building (at times of your own convenience) for the purposes of this study?

Exclusion Criteria:

  • Oral antibiotic treatment within the past month?
  • Have a history or current diagnosis of irritable bowel syndrome?
  • Have a history or current diagnosis of inflammatory bowel disease?
  • Have a history or current diagnosis of type 2 diabetes?
  • Have a history or current diagnosis of chronic kidney disease with decreased kidney function?
  • Have a history or current diagnosis of intestinal obstruction?
  • Have a history or current diagnosis of untreated colorectal cancer?
  • Have you had a colonoscopy within the past month?
  • Had oral antibiotics within the past month?
  • Do you consume one entire non-snack meal or more per week in liquid form (smoothie, meal replacement drink, etc.)?
  • Do you have any dental issues or other physical limitations that would prevent you from thoroughly chewing your food?
  • Do you currently practice any mindfulness or dietary techniques that involve making sure that your food is chewed thoroughly?

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Basic Science
  • Allocation: N/A
  • Interventional Model: Single Group Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: Control + Intervention
We will explore our hypothesis using a fixed-order within-subjects study design in a group of healthy participants. Each participant will have one week of normal dietary habits and one week of increased chewing time. We will collect stool samples three times per week in order to measure microbial abundance and metabolism.
Participants will have one week of increased chewing time (chew food until they reach an apple sauce consistency)

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Time Frame
• Change in short-chain fatty acid (SCFA) measured in stool samples by gas chromatography
Time Frame: 1 week baseline and 1 week intervention
1 week baseline and 1 week intervention

Secondary Outcome Measures

Outcome Measure
Time Frame
Change in median fecal particle size as measured by laser diffraction
Time Frame: 1 week baseline and 1 week intervention
1 week baseline and 1 week intervention
Change in gut microbiome composition as measured by 16S rRNA-encoding gene amplicon sequence analysis
Time Frame: 1 week baseline and 1 week intervention
1 week baseline and 1 week intervention

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Investigators

  • Principal Investigator: Lawrence David, Duke University - MGM

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

October 26, 2021

Primary Completion (Actual)

April 1, 2022

Study Completion (Actual)

April 1, 2022

Study Registration Dates

First Submitted

October 13, 2021

First Submitted That Met QC Criteria

October 13, 2021

First Posted (Actual)

October 25, 2021

Study Record Updates

Last Update Posted (Actual)

April 14, 2022

Last Update Submitted That Met QC Criteria

April 12, 2022

Last Verified

September 1, 2021

More Information

Terms related to this study

Other Study ID Numbers

  • Pro00108805

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Intervention

3
Subscribe